Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy

Area of Science:

• Immunology
• Pediatric Rheumatology
• Molecular Biology

Background:

• Juvenile dermatomyositis (JDM) is an autoimmune disease with complex pathogenesis.
• The interferon (IFN) pathway has emerged as a significant factor in JDM development and progression.

Purpose of the Study:

• To review the current understanding of the role of interferon (IFN) in juvenile dermatomyositis (JDM).
• To compare JDM to interferonopathies and discuss therapeutic implications of targeting IFN signaling.

Main Methods:

• Review of transcriptomic and protein-based studies.
• Analysis of peripheral IFN-α assessment.
• Examination of gene and protein expression in blood and muscle tissues.

Main Results:

• Dysregulated IFN pathways are crucial in JDM, correlating with disease activity and potentially predicting flares.
• Type I and II IFN are dysregulated in JDM, with type I IFN prominent in skin lesions.
• Muscle studies link hypoxia to IFN production, vascular dysfunction, and atrophy, with JDM showing overlap with interferonopathy phenotypes.
• Janus kinase (JAK) inhibitors have shown promise in refractory JDM by decreasing IFN markers and improving clinical outcomes.

Conclusions:

• IFN, particularly type I and II, is integral to JDM pathogenesis, mirroring muscle pathology and correlating with disease activity.
• While differences may exist based on autoantibody profiles, further validation is required.
• JAK inhibitors represent a promising therapeutic strategy for JDM by inhibiting IFN signaling, though further research on patient selection, dosing, and safety is necessary.